Moderna (MRNA) Net Cash Flow (2018 - 2026)

Moderna (MRNA) has reported Net Cash Flow for 9 consecutive years, with -$183.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Net Cash Flow rose 47.11% year-over-year to -$183.0 million in Q2 2026; TTM through Jun 2026 was $443.0 million, a 136.92% increase from a year earlier, with the FY2025 full-year figure at $666.0 million, up 166.67% from the prior year.
• Net Cash Flow was -$183.0 million for Q2 2026 at Moderna, up from -$689.0 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $1.5 billion in Q4 2025 and troughed at -$2.2 billion in Q2 2022.
• A 5-year average of -$285.4 million and a median of -$165.5 million in 2025 frame the typical range for Net Cash Flow.
• Across the five-year window, Net Cash Flow tumbled 1450.93% in 2022 and surged 1232.0% in 2024, its largest moves.
• Over 5 years, Net Cash Flow stood at $176.0 million in 2022, then slumped by 114.2% to -$25.0 million in 2023, then surged by 1232.0% to $283.0 million in 2024, then soared by 416.96% to $1.5 billion in 2025, then plunged by 112.51% to -$183.0 million in 2026.
• The last three Net Cash Flow figures came in at -$183.0 million (Q2 2026), -$689.0 million (Q1 2026), and $1.5 billion (Q4 2025), per Business Quant data.